Afatinib restrains K-RAS-driven lung tumorigenesis

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Previous research established that V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (K-RAS) mutations confer resistance to first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC).
• This doctrine, however, overlooks the role of EGFR signaling in K-RAS-driven lung tumorigenesis.

Purpose of the Study:

• To investigate the role of EGFR signaling in K-RAS-driven lung tumorigenesis.
• To evaluate the efficacy of pan-ERBB inhibitors in overcoming resistance mechanisms in K-RAS-mutated NSCLC.

Main Methods:

• Utilized genetically engineered mouse models with K-RAS mutations and EGFR deletion.
• Employed patient-derived and cell line-derived xenografts.
• Conducted in vitro experiments and analyzed EGFR signaling pathways.

Main Results:

• EGFR signaling is integral to K-RAS-driven lung tumorigenesis.
• EGFR deletion in mouse models reduced K-RAS activity and transiently inhibited tumor growth.
• EGFR inhibition triggered resistance via non-EGFR ERBB family members, explaining the failure of first-generation TKIs.
• The pan-ERBB inhibitor afatinib demonstrated significant efficacy against K-RAS-driven lung tumorigenesis in various models.

Conclusions:

• EGFR signaling plays a crucial role in K-RAS-driven lung cancer.
• Pan-ERBB inhibitors, such as afatinib, represent a promising therapeutic strategy for K-RAS-mutated NSCLC by targeting resistance mechanisms.
• Clinical trials investigating pan-ERBB inhibition for K-RAS-mutated NSCLC are warranted.